Akari Therapeutics to Showcase RNA Splicing ADC Platform at Key Oncology Conferences
Event summary
- Akari Therapeutics selected to present at five high-profile oncology and ADC conferences in September 2026.
- CEO Abizer Gaslightwala to deliver keynotes and panel discussions on PH1 ADC payload platform.
- Company aims to highlight PH1 platform's potential for differentiated ADCs and global R&D collaborations.
- Akari advancing AKTX-101 toward first-in-human clinical trial by mid-2027.
- PH1 payload targets RNA splicing, offering novel mechanism for cancer cell death and immune activation.
The big picture
Akari's participation in these conferences underscores the growing industry focus on novel ADC payloads. The company's PH1 platform, targeting RNA splicing, represents a strategic shift from traditional microtubule inhibitors and DNA-damaging agents. As the oncology sector increasingly values differentiated payloads, Akari's ability to showcase its technology could attract potential partners and investors. The company's lead candidate, AKTX-101, is poised to enter clinical trials by mid-2027, marking a critical milestone in its development strategy.
What we're watching
- Partnership Potential
- Whether Akari can secure strategic collaborations to advance its PH1 platform.
- Clinical Timeline
- The pace at which AKTX-101 progresses toward first-in-human trials.
- Market Differentiation
- How Akari's RNA splicing payload will position it against traditional ADC payloads.
Related topics